Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Jingquan Jia
Dasatinib (BMS-35482) Interacts Synergistically With Docetaxel, Gemcitabine, Topotecan, and Doxorubicin in Ovarian Cancer Cells With High SRC Pathway Activation and Protein Expression
International Journal of Gynecological Cancer
Gynecology
Oncology
Obstetrics
Related publications
Paclitaxel and Ceramide Synergistically Induce Cell Death With Transient Activation of EGFR and ERK Pathway in Pancreatic Cancer Cells
Oncology Reports
Medicine
Cancer Research
Oncology
Topotecan in Ovarian Cancer
Oncologist
Cancer Research
Medicine
Oncology
Topotecan Synergizes With CHEK1 (CHK1) Inhibitor to Induce Apoptosis in Ovarian Cancer Cells
BMC Cancer
Cancer Research
Oncology
Genetics
Combination Therapy With Gossypol Reveals Synergism Against Gemcitabine Resistance in Cancer Cells With High BCL-2 Expression
PLoS ONE
Multidisciplinary
Role of SRC Expression and Activation in Human Cancer
Oncogene
Cancer Research
Genetics
Molecular Biology
A Phase I Trial of Dasatinib, an SRC-Family Kinase Inhibitor, in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Recurrent Ovarian Cancer
Clinical Cancer Research
Cancer Research
Oncology
Activity of the Multikinase Inhibitor Dasatinib Against Ovarian Cancer Cells
British Journal of Cancer
Cancer Research
Oncology
Phase I Trial of Weekly Topotecan and Gemcitabine in Patients With Solid Tumors
American Journal of Clinical Oncology: Cancer Clinical Trials
Cancer Research
Oncology
Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
